Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Operating Leases for 7 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 661.2% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 661.2% increase, with the full-year FY2025 number at $7.7 million, up 661.2% from a year prior.
  • Operating Leases was $7.7 million for Q4 2025 at Madrigal Pharmaceuticals, up from $5.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.7 million in Q4 2025 to a low of $71000.0 in Q3 2022.
  • A 5-year average of $1.6 million and a median of $900000.0 in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 85.54% in 2022, then soared 1763.38% in 2023.
  • Madrigal Pharmaceuticals' Operating Leases stood at $387000.0 in 2021, then tumbled by 81.65% to $71000.0 in 2022, then soared by 1570.42% to $1.2 million in 2023, then decreased by 14.17% to $1.0 million in 2024, then surged by 661.2% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Operating Leases are $7.7 million (Q4 2025), $5.6 million (Q3 2025), and $4.5 million (Q2 2025).